1. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Author
-
Lee, Hans C, Saliba, Rima M, Rondon, Gabriela, Chen, Julianne, Charafeddine, Yasmeen, Medeiros, L Jeffrey, Alatrash, Gheath, Andersson, Borje S, Popat, Uday, Kebriaei, Partow, Ciurea, Stefan, Oran, Betul, Shpall, Elizabeth, and Champlin, Richard
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Pediatric ,Transplantation ,Regenerative Medicine ,Hematology ,Cancer ,Stem Cell Research ,Pediatric Cancer ,Rare Diseases ,Clinical Research ,Adult ,Busulfan ,Female ,Graft Survival ,Graft vs Host Disease ,Hematopoietic Stem Cell Transplantation ,Humans ,Leukemia ,Myeloid ,Acute ,Male ,Middle Aged ,Myeloablative Agonists ,Myelodysplastic Syndromes ,Prognosis ,Recurrence ,Remission Induction ,Retrospective Studies ,Survival Analysis ,T-Lymphocytes ,Transplantation Chimera ,Transplantation Conditioning ,Transplantation ,Homologous ,Vidarabine ,Acute myeloid leukemia ,Chimerism ,Myelodysplastic syndrome ,Relapse ,Clinical Sciences ,Immunology ,Cardiovascular medicine and haematology - Abstract
Chimerism testing after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) represents a promising tool for predicting disease relapse, although its precise role in this setting remains unclear. We investigated the predictive value of T lymphocyte chimerism analysis at 90 to 120 days after allo-HSCT in 378 patients with AML/MDS who underwent busulfan/fludarabine-based myeloablative preparative regimens. Of 265 (70%) patients with available T lymphocyte chimerism data, 43% of patients in first or second complete remission (CR1/CR2) at the time of transplantation had complete (100%) donor T lymphocytes at day +90 to +120 compared with 60% of patients in the non-CR1/CR2 cohort (P = .005). In CR1/CR2 patients, donor T lymphocyte chimerism ≤ 85% at day +90 to +120 was associated with a higher frequency of 3-year disease progression (29%; 95% confidence interval [CI], 18% to 46% versus 15%; 95% CI, 9% to 23%; hazard ratio [HR], 2.1; P = .04). However, in the more advanced, non-CR1/CR2 cohort, mixed T lymphocyte chimerism was not associated with relapse (37%; 95% CI, 20% to 66% versus 34%; 95% CI, 25% to 47%; HR, 1.3; P = .60). These findings demonstrate that early T lymphocyte chimerism testing at day +90 to +120 is a useful approach for predicting AML/MDS disease recurrence in patients in CR1/CR2 at the time of transplantation.
- Published
- 2015